August 31st, 2014
Entrusting Imaging to Robotic Hands: The Potential of Remote Echocardiography and Tele-Consultation
Jagat Narula, MD, DM, PhD, MACC, FAHA, FRCP
CardioExchange’s Harlan M. Krumholz interviews Dr. Jagat Narula about his research group’s study of remote, robot-assisted echocardiographic technology and its applications worldwide.
August 31st, 2014
Preliminary Outcomes Results For PCSK9 Inhibitor
Larry Husten, PHD
Amid a slew of new data demonstrating yet again that PCSK9 inhibitors lower LDL cholesterol—drastically and in a wide variety of different patient populations—data from one trial offers the first suggestion that the drugs may in fact improve cardiovascular outcomes. But the analysis, the authors cautioned, is a post-hoc analysis of a trial neither designed nor […]
August 31st, 2014
SIGNIFY Trial Provokes Sound and Fury Over Controversial Drug
Larry Husten, PHD
The already controversial drug ivabradine just got a little more controversial. The drug, which is marketed by Servier under the brand names of Corlentor and Procoralan, is available in Europe and elsewhere and is used for the treatment of heart failure and stable angina. The drug is not available in the U.S., but it is under development by Amgen for a […]
August 30th, 2014
ESC.14 Headquarters
wpengine
CardioExchange is dedicated to bringing you the latest from ESC.14. Check out our coverage of the conference here at CardioExchange and don’t forget to tell us what you think! News: PARADIGM-HF Establishes a New Paradigm for Heart Failure Treatment SIGNIFY Trial Provokes Sound and Fury Over Controversial Drug Preliminary Outcomes Results For PCSK9 Inhibitor New Support […]
August 30th, 2014
Will There Be a PARADIGM Shift in Treatment of Heart Failure?
John McMurray, MbChB MD and Milton Packer, MD
John J.V. McMurray and Milton Packer, the two lead authors of the PARADIGM-HF trial, discuss the randomized comparison of angiotensin–neprilysin inhibition with the ACE inhibitor enalapril.
August 30th, 2014
PARADIGM-HF Establishes a New Paradigm for Heart Failure Treatment
Larry Husten, PHD
So far as I can tell the only problem with PARADIGM-HF is that the results are so good that it’s boring. Anyone interested can reasonably assume that what they hear or read about PARADIGM-HF — and cardiologists will be seeing and hearing an awful lot about it — will be overwhelmingly positive. Briefly, the trial did […]
August 28th, 2014
Predicting PARADIGM-HF, or What to Expect When You’re Expecting
Larry Husten, PHD
Larry Husten analyzes the expectations surrounding the upcoming release of PARADIGM-HF and its centerpiece LCZ696 from the perspective of the medical field as well as the world of economics.
August 25th, 2014
Rise in Popularity of E-Cigarettes Sparks Concerns and Recommendations
Larry Husten, PHD
The recent dramatic rise in popularity of e-cigarettes threatens to reverse hard-fought progress in the war against smoking, according to a new policy statement from the American Heart Association. “E-cigarettes have caused a major shift in the tobacco-control landscape,” said the lead author of the statement, Aruni Bhatnagar, chair of cardiovascular medicine at the University of Louisville. But […]
August 25th, 2014
An Electrophysiology Service Diagnostic Conundrum
Seth Shay Martin, MD and James Fang, MD
A 57-year-old woman with paroxysmal atrial fibrillation, long-QT syndrome after ICD implantation, and severe anxiety presents a unique diagnostic challenge.
August 21st, 2014
FDA Grants Apixaban Expanded Indication for Venous Thromboembolism
Larry Husten, PHD
The FDA today approved an expanded indication for the oral anticoagulant apixaban (Eliquis, Bristol-Myers Squibb and Pfizer). Apixaban will now be indicated for the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE), and for the reduction in the risk of recurrent DVT and PE (collectively known as venous thromboembolism) after initial therapy. The supplemental new […]